Previous Close | 55.50 |
Open | 54.88 |
Bid | 55.17 x 1000 |
Ask | 55.50 x 3200 |
Day's Range | 54.64 - 55.21 |
52 Week Range | 46.93 - 58.10 |
Volume | |
Avg. Volume | 2,277,998 |
Market Cap | 138.102B |
Beta (5Y Monthly) | 0.36 |
PE Ratio (TTM) | 19.47 |
EPS (TTM) | 2.83 |
Earnings Date | N/A |
Forward Dividend & Yield | 1.80 (3.24%) |
Ex-Dividend Date | May 26, 2022 |
1y Target Est | 70.75 |
Subscribe to Yahoo Finance Plus to view Fair Value for SNY
Over the past six months, the market has fallen sharply thanks to a toxic combination of fears about a looming recession, rising inflation, and rising interest rates. Growth stocks and unprofitable companies have been especially hard hit. Sanofi (NASDAQ: SNY) is a multinational pharma giant with a market cap in excess of $135 billion, and its shares are up by over 17% from six months ago.
Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.